American Heart Journal
Volume 148, Issue 1, Supplement , Pages S14-S18 , July 2004

Focus on high-density lipoproteins in reducing cardiovascular risk

  • H.Bryan Brewer Jr, MD

      Affiliations

    • Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md, USA
    • Corresponding Author InformationReprint requests: H. Bryan Brewer, Jr, MD, Chief, Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Building 10–Magnuson CC, Room 7N115, 10 Center Drive, MSC-1666, Bethesda, MD 20892, USA.

References 

  1. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease—the Framingham Study. Can J Cardiol. 1988;4(Suppl A):5–10A
  2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. Bethesda (Md): National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health; September 2002. NIH Publication 02-5215
  3. Brewer HB, Santamarina-Fojo S. New insights into the role of the adenosine triphosphate–binding cassette transporters in high-density lipoprotein metabolism and reverse cholesterol transport. Am J Cardiol. 2003;91:3–11E
  4. Mackness MI, Arrol S, Abbott C, et al.  Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993;104:129–135
  5. Marathe GK, Zimmerman GA, McIntyre TM. Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J Biol Chem. 2003;278:3937–3947
  6. Barter PJ, Baker PW, Rye KA. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol. 2002;13:285–288
  7. Glomset JA. The plasma lecithins (cholesterol acyltransferase reaction). J Lipid Res. 1968;9:155–167
  8. Oram JF, Lawn RM. ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J Lipid Res. 2001;42:1173–1179
  9. Malerod L, Juvet LK, Hanssen-Bauer A, et al.  Oxysterol-activated LXRalpha/RXR induces hSR-BI-promoter activity in hepatoma cells and preadipocytes. Biochem Biophys Res Commun. 2002;299:916–923
  10. Costet P, Luo Y, Wang N, et al.  Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem. 2000;275:28240–28245
  11. Schwartz K, Lawn RM, Wade DP. ABC1 gene expression and ApoA-I-mediated cholesterol efflux are regulated by LXR. Biochem Biophys Res Commun. 2000;274:794–802
  12. Williams DL, Connelly MA, Temel RE, et al.  Scavenger receptor BI and cholesterol trafficking. Curr Opin Lipidol. 1999;10:329–339
  13. Basso F, Freeman L, Knapper CL, et al.  Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations. J Lipid Res. 2003;44:296–302
  14. Brewer HB, Santamarina-Fojo S. Clinical significance of high-density lipoproteins and the development of atherosclerosis (focus on the role of the adenosine triphosphate–binding cassette protein A1 transporter). Am J Cardiol. 2003;92:10–16K
  15. Guerin M, Lassel TS, Le Goff W, et al.  Action of atorvastatin in combined hyperlipidemia. Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol. 2000;20:189–197
  16. Rubin EM, Krauss RM, Spangler EA, et al.  Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991;353:265–267
  17. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA. 1994;91:9607–9611
  18. Nissen SE, Tsunoda T, Tuzcu EM, et al.  Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes (a randomized controlled trial). JAMA. 2003;290:2292–2300
  19. Remaley AT, Thomas F, Stonik JA, et al.  Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J Lipid Res. 2003;44:828–836
  20. Hirano K, Yamashita S, Matsuzawa Y. Pros and cons of inhibiting cholesteryl ester transfer protein. Curr Opin Lipidol. 2000;11:589–596
  21. Okamoto H, Yonemori F, Wakitani K, et al.  A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000;406:203–207

PII: S0002-8703(04)00228-5

doi: 10.1016/j.ahj.2004.04.027

American Heart Journal
Volume 148, Issue 1, Supplement , Pages S14-S18 , July 2004

Article Tools

* Image Usage & Resolution